Altered prevalence and reactivity of anti-Epstein-Barr virus antibodies in patients with multiple sclerosis

H. J. Wagner*, H. Hennig, W. J. Jabs, A. Siekhaus, K. Wessel, K. P. Wandinger

*Corresponding author for this work
29 Citations (Scopus)

Abstract

In this study, the prevalence and reactivity of anti-Epstein-Barr virus (EBV) antibodies were investigated in 107 patients with multiple sclerosis (MS) in comparison to age- and gender-matched healthy controls from a north German state. We found a significant 100% EBV-seropositivity and a significant lack of primary EBV infections in the MS group, indicating that all MS patients are infected with EBV before the development of MS. Although there were no differences in reactivities of EBV-specific anti-early antigen (EA)-immunoglobulin G (IgG), -IgM, and -IgA antibodies between each group, MS patients had significant lower anti-Epstein-Barr nuclear antigen (EBNA)1-IgG antibody titers as a possible serological sign for a defective control of the persistent latent EBV carrier state and EBV reactivations. Longitudinal studies of MS patients are necessary to further determine the implications of EBV reactivations on the course and disease activity of MS.

Original languageEnglish
JournalViral Immunology
Volume13
Issue number4
Pages (from-to)497-502
Number of pages6
ISSN0882-8245
DOIs
Publication statusPublished - 2000

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Fingerprint

Dive into the research topics of 'Altered prevalence and reactivity of anti-Epstein-Barr virus antibodies in patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this